Clinical trials: Uric Acid
Obesity, Uric Acid Stones
Phentermine/Topiramate for Uric Acid Stones
The investigator proposes an 18 month, feasibility pilot study, randomizing obese and diabetic individuals with pure uric acid nephrolithiasis (UAN) or mixed calcium oxalate (CO) UAN to either phentermine/topiramate or a…
- Conditions
- Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese, Pre-Diabetes
- Trial name
- NCT04621929
- Testing
- Phentermine / Topiramate Oral Product, Citrate Salts, Allopurinol, Diet
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Florida
Diabetic Kidney Disease, Hyperuricemia
Uric Acid Lowering Trial in Youth Onset T2D
Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D).
- Conditions
- Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2
- Trial name
- ULTRA-T2D (NCT03899883)
- Testing
- Pegloticase 8 MG/ML [Krystexxa]
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Healthy
A Food-Drug Interaction Study of Serum Urate After Oral Inosine
The purpose of this study is to assess the effects of food on the amount of urate in the body after a single oral dose of inosine.
- Trial name
- NCT02614469
- Testing
- Inosine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Michael Alan Schwarzschild
Kidney Disease
Uric Acid and the Endothelium in CKD
This study will test the hypothesis that uric acid impairs the function of vessels in patients with kidney disease
- Trial name
- NCT01228903
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Colorado, Denver
Gout, Chronic Kidney Disease (CKD)
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of serum urate (sUA).
- Trial name
- NCT03226899
- Testing
- Lesinurad, XOI, colchicine
- Where
- 116 sites in United States, Czechia and 2 more
- Volunteers
- 242 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Acute Gouty Arthritis
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
This is a 36 week open-label extension of the canakinumab pre-filled syringe study for safety and tolerability in patients who have frequent flares of acute gouty arthritis.
- Trial name
- NCT01431638
- Testing
- Canakinumab 150mg in prefilled syringe
- Where
- 68 sites in United States, Canada and 2 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoma
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
The goal of this clinical research study is to learn if using Elitek (rasburicase) for 2 cycles can help to control or prevent TLS better than 1 cycle of rasburicase and 1 cycle of allopurinol.
- Trial name
- NCT01200485
- Testing
- Rasburicase, Allopurinol
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Joint Damage
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.
- Trial name
- NCT01078389
- Testing
- Febuxostat
- Where
- 56 sites in United States
- Volunteers
- 314 people
- Sponsor
- Takeda
Gout
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.
- Trial name
- EXCEL (NCT00175019)
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 1,086 people
- Sponsor
- Takeda
IgA Nephropathy
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.
- Trial name
- NCT00793585
- Testing
- allopurinol, continue their usual therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Nephrolithiasis, Uric Acid
Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss
The investigators will randomize overweight and obese iuan patients to Pio (45 mg/day, highest approved dose or placebo), WL (10% of body weight, following the established program used in the Diabetes Prevention Program), or…
- Trial name
- NCT04370093
- Testing
- Pioglitazone 45 mg, Weight Loss, Pioglitazone + Weight Loss
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
Gout
An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
The purpose of this study is to show that patients with gout suffer from chronic inflammation of their joints, observable by MRI, even in the absence of symptomatic gouty attacks.
- Trial name
- NCT01112982
- Testing
- Magnetic Resonance Imaging, Febuxostat, Colchicine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of South Florida
Parkinson's Disease
Study of Urate Elevation in Parkinson's Disease, Phase 3
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early…
- Trial name
- SURE-PD3 (NCT02642393)
- Testing
- Inosine
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 298 people
- Sponsor
- Michael Alan Schwarzschild
Amyotrophic Lateral Sclerosis
A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
This is a single center, open label, 12-week study of inosine treatment. Inosine treatment leads to an increase in the levels of urate (uric acid) in the blood.
- Trial name
- NCT02288091
- Testing
- Inosine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Gout
To Evaluate the Influence of (LUA Probiotics) on Uric Acid
This study aims to investigate the efficacy of the lactic acid bacteria "LUA probiotics" in reducing serum uric acid levels. The use of health supplements prior to the onset of gout symptoms is proposed as a preventive strategy…
- Trial name
- NCT06969469
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Grape King Bio Ltd.
Obesity, Metabolic Syndrome
Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status
The purpose of this study is to learn more about what is the effect of uric acid on oxidative stress and on the way the body metabolizes sugar in obese people. Understanding this may lead to better diseases such as diabetes.
- Conditions
- Obesity, Metabolic Syndrome, Hyperuricemia
- Trial name
- UA (NCT01931527)
- Testing
- Rasburicase
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Washington University School of Medicine
Renal Impairment
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
The purpose of this study is to determine the effect of febuxostat, once daily (QD) or twice daily (BID), on renal function in gout patients with elevated serum urate levels and who have moderate to severe renal impairment.
- Trial name
- NCT01082640
- Testing
- Febuxostat
- Where
- 58 sites in United States
- Volunteers
- 96 people
- Sponsor
- Takeda
Pre-hypertension, JNC 7 Stage I Hypertension
Center of Research Translation (CORT) Project 2
We propose a novel intervention for reducing BP that could have a preferential impact in patients with hyperuricemia and gout. There is a great need for new anti-hypertensives, particularly among those with gout.
- Trial name
- NCT02038179
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Cardiovascular Disease
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).
- Trial name
- CARES (NCT01101035)
- Testing
- Febuxostat, Allopurinol
- Where
- 203 sites in United States, Mexico
- Volunteers
- 6,198 people
- Sponsor
- Takeda
Intercritical Gout
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning allopurinol treatment for gout.
- Trial name
- PRE-SURGE1 (NCT00829829)
- Testing
- Rilonacept 80 mg, Rilonacept 160 mg
- Where
- 91 sites in United States, Canada
- Volunteers
- 241 people
- Sponsor
- Regeneron Pharmaceuticals